Transplant Complications Working Party (TCWP)
Study type:
Study number:
84110113
Type of treatment:
Allogeneic
Diseases:
All diseases
Short title:
TA-TMA severity score
Primary objective:
Identify the risk factors that impact Overall Survival after TA-TMA after allo (related to the patient, previous allogeneic transplantation and diagnosis criteria at time of TA-TMA diagnosis)
Key inclusion criteria:
1) Last allogeneic stem cell transplantation between 2019-2024
2) TA-TMA diagnosed under institutional guidelines
3) Age ≥18 years at HCT
4) All cell sources
5) All donor types (related, unrelated, haploidentical)
6) Diagnosis of haematological malignancy
2) TA-TMA diagnosed under institutional guidelines
3) Age ≥18 years at HCT
4) All cell sources
5) All donor types (related, unrelated, haploidentical)
6) Diagnosis of haematological malignancy
Country:
All EBMT member countries
Principal investigator:
Ivan Moiseev
EBMT Study coordinator:
William Boreland
Study coordinator email:
william.boreland@ebmt.org
EBMT Study Unit:
Paris Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Paris Study Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results